[{"address1": "260 Sheridan Avenue", "address2": "Suite 400", "city": "Palo Alto", "state": "CA", "zip": "94306", "country": "United States", "phone": "650 800 6676", "website": "https://vincerx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. The company is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors. Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 and is based in Palo Alto, California.", "fullTimeEmployees": 42, "maxAge": 86400, "priceHint": 4, "previousClose": 0.601, "open": 0.6021, "dayLow": 0.6, "dayHigh": 0.6336, "regularMarketPreviousClose": 0.601, "regularMarketOpen": 0.6021, "regularMarketDayLow": 0.6, "regularMarketDayHigh": 0.6336, "beta": 1.106, "forwardPE": -0.7894737, "volume": 227233, "regularMarketVolume": 227233, "averageVolume": 748254, "averageVolume10days": 171290, "averageDailyVolume10Day": 171290, "bid": 0.5776, "ask": 0.6492, "bidSize": 100, "askSize": 100, "marketCap": 17720520, "fiftyTwoWeekLow": 0.6, "fiftyTwoWeekHigh": 9.372, "fiftyDayAverage": 0.7723, "twoHundredDayAverage": 1.68333, "currency": "USD", "enterpriseValue": 14829543, "floatShares": 23278886, "sharesOutstanding": 29534200, "sharesShort": 567512, "sharesShortPriorMonth": 1196271, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.019199999, "heldPercentInsiders": 0.18273, "heldPercentInstitutions": 0.37271, "shortRatio": 1.15, "shortPercentOfFloat": 0.024500001, "impliedSharesOutstanding": 29534200, "bookValue": -0.029, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -37936000, "trailingEps": -1.78, "forwardEps": -0.76, "enterpriseToEbitda": -0.428, "52WeekChange": -0.53846157, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "VINC", "underlyingSymbol": "VINC", "shortName": "Vincerx Pharma, Inc.", "longName": "Vincerx Pharma, Inc.", "firstTradeDateEpochUtc": 1590586200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "46789548-9ff1-3829-9a39-73e43f85b2b7", "messageBoardId": "finmb_690173412", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.6, "targetHighPrice": 10.0, "targetLowPrice": 4.0, "targetMeanPrice": 7.0, "targetMedianPrice": 7.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 5110000, "totalCashPerShare": 0.173, "ebitda": -34627000, "totalDebt": 2219000, "quickRatio": 0.577, "currentRatio": 0.722, "returnOnAssets": -0.74060994, "returnOnEquity": -2.24182, "freeCashflow": -16488375, "operatingCashflow": -35100000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]